A Scoping Review of Interactions between Omega-3 Long-Chain Polyunsaturated Fatty Acids and Genetic Variation in Relation to Cancer Risk

Karin Yurko-Mauro 1,*, Mary Van Elswyk 2 and Lynn Teo 3

1 Pharma Segment, DSM Nutritional Products, Columbia, MD 21045, USA
2 Van Elswyk Consulting, Inc., Clark, CO 80428, USA; mveconsulting@q.com
3 Teo Research Consulting, Silver Spring, MD 20910, USA; teoresearchconsulting@gmail.com

* Correspondence: kymauro20@gmail.com

Received: 3 April 2020; Accepted: 28 May 2020; Published: 2 June 2020

Abstract: This scoping review examines the interaction of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) and genetic variants of various types of cancers. A comprehensive search was performed to identify controlled and observational studies conducted through August 2017. Eighteen unique studies were included: breast cancer (n = 2), gastric cancer (n = 1), exocrine pancreatic cancer (n = 1), chronic lymphocytic leukemia (n = 1), prostate cancer (n = 7) and colorectal cancer (n = 6). An additional 13 studies that focused on fish intake or at-risk populations were summarized to increase readers’ understanding of the topic based on this review, DHA and EPA interact with certain genetic variants to decrease breast, colorectal and prostate cancer risk, although data was limited and identified polymorphisms were heterogeneous. The evidence to date demonstrates that omega-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) may decrease cancer risk by affecting genetic variants of inflammatory pathways, oxidative stress and tumor apoptosis. Collectively, data supports the notion that once a genetic variant is identified, the benefits of a targeted, personalized therapeutic regimen that includes DHA and/or EPA should be considered.

Keywords: polyunsaturated fatty acids; omega-3; docosahexaenoic acid; eicosapentaenoic acid; cancer; genes; genetic variation; genotype; scoping review

1. Introduction

Cancer is a growing global burden. In 2018, there was an estimated 18.1 million cancer cases and 9.6 million cancer deaths worldwide [1]. Globally, the leading types of cancer among men are lung, prostate and stomach cancers that represent 14.5%, 13.5% and 7.2% of all new cases, respectively. In women, breast, lung and cervical cancers are the leading cancer types with 24.2%, 8.4% and 6.6% of new cases, respectively. [1]. According to a National Vital Statistic Report released in 2019, cancer was the second leading cause of death (exceeded by heart disease) and 21.4% of deaths in the US were due to cancer in 2017 [2]. While considerable progress has been made in the diagnosis and treatment of many cancers, standard treatments not only cause apoptosis of the cancer cells, but also surrounding healthy cells and tissues. This leads to weakened and dysfunctional tissue, and contributes to adverse events, such as fatigue, nausea, muscle loss, diarrhea or constipation. Such side effects can be severe and lead to dose reductions or the discontinuation of the drug treatment. More tailored, personalized medicine and nutritional approaches based on genetics, drug responsiveness, and immune function, along with an optimal diet are being advanced as therapies for cancer treatment.
Omega-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA), such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are important fatty acids that may play a role in preventing some cancers and act as adjunct therapy to chemotherapeutics, immunotherapeutics, or radiation [3]. While the n-3 LC-PUFA precursor, alpha-linolenic acid (ALA), is often more prevalent in the diet than DHA and EPA, it is recognized that the conversion of ALA to downstream metabolites is limited and considered insufficient to support tissue n-3 LC-PUFA levels that are associated with various biological outcomes [4]. The same is true for the production and intake of intermediate n-3 LC-PUFA, such as docosapentaenoic acid (DPA), the effects and mechanisms of action of which are poorly understood [4]. With regard to cancer risk in particular, evidence suggests a limited role of ALA in reducing development of various tumor types, yet greater biopotency of preformed DHA and EPA in a variety of pathways related to cancer risk reduction [5–7].

N-3 LC-PUFA have pleiotropic effects and enhance cancer cell apoptosis, modulate various eicosanoid pathways leading to reduced inflammation, such as suppressing cyclooxygenase-2 (COX-2) synthesis and the inhibition of arachidonic acid-derived eicosanoids [8]. Importantly, N-3 LC-PUFA’s anti-neoplastic activity may derive from their incorporation into cell membranes to optimize receptor function and signaling pathways, including inhibiting Ras/ERK pathway and phosphoinositide signaling (e.g., AKT inactivation) [9,10] which may arrest cancer cell growth. Their ability to increase intracellular oxidative stress [11] and to bind to nuclear receptors to modulate gene expression paths of apoptosis [12] are also potential anti-cancer mechanisms. Animal studies and human observational studies have demonstrated that n-3 LC-PUFA may reduce the risk of cancers such as breast, colon and prostate [8,10,13]. The effects of n-3 LC-PUFA, however, may be modulated by specific genes or genetic variants of cancer phenotypes leading to variations in therapeutic response [14]. For example, a case-control study by Fradet et al. (2009) found that greater intake of n-3 LC-PUFA was significantly associated with lower prostate cancer (PCA) risk in those with the cyclooxygenase-2 (COX-2) single nucleotide polymorphism (SNP) rs4648310 [15]. While some other studies have demonstrated similar positive effects of n-3 LC-PUFA on specific genetic variants of cancer [11,16], other studies have had null or mixed results [17,18] and many studies have not explored such genotype-dependent effects.

This scoping review was undertaken to identify human studies that examined the effects of preformed n-3 LC-PUFA, namely DHA and EPA, on genetic variants of any type of cancer. Both observational and interventional studies are included. The goal is to better understand associations between preformed n-3 LC-PUFA intake or tissue levels and genotype-specific cancer risk, and to understand variability in individual responses to n-3 LC-PUFA supplementation in order to provide a targeted, personalized therapeutic approach to cancer treatment.

2. Materials and Methods

2.1. Study Inclusion and Exclusion Criteria

Human studies were included if they met the following criteria: (1) peer-reviewed publications of trials, including controlled trials (randomized or non-randomized) or observational trials; (2) involving healthy subjects or cancer patients; where (3) n-3 LC-PUFA (DHA and/or EPA) were given as an intervention or DHA and/or EPA blood or tissue levels were measured or the intake of DHA and/or EPA was reported; (4) and the association with risk of cancer by genotype or expression of genes involved in carcinogenesis was measured. All types of control/comparators were considered for inclusion.

Case reports, protocols, conference abstracts, letters, commentaries as well as animal or cell-line studies were excluded. Studies in which the independent effects of DHA and/or EPA could not be isolated due to combination with another active ingredient or not separately analyzed in the diet or tissue from other n-3 LC-PUFA (e.g., alpha-linolenic acid, docosapentaenoic acid, etc.) were also excluded.
2.2. Data Sources and Search Strategy

PubMed, Embase, Scopus, World of Science and Cochrane’s CENTRAL were searched from their database inception through August 2017. All searches were restricted to the peer-reviewed studies involving human subjects. See Figure 1 for the PubMed search string that was executed. The variations used for other databases can be accessed by contacting the corresponding author. Systematic reviews, meta-analyses and Clinicaltrials.gov were also scanned for salient references.

2.3. Study Selection

Two investigators (L.T. and M.V.E.) independently screened titles and abstracts of all citations yielded from the literature search in duplicate using the pre-defined study eligibility criteria. Conflicts regarding inclusion of citations were resolved by consensus between the two investigators and when consensus could not be reached, a third party was consulted (K.Y.M). Full texts were acquired for any abstract meeting all eligibility criteria or for those where eligibility could not be determined. Full-texts of abstracts reporting only fish intake were acquired to see if DHA or EPA intake or tissue levels were reported. If not reported in the full text, authors of these studies were contacted; contacted authors either did not respond or replied that these levels were not measured. During this process, recognizing the limited data available for preformed DHA and EPA, the authors elected to summarize and include in the evidence map, studies reporting only fish intake since fish is the primary source of EPA and DHA.

Studies reporting only fish intake as well as studies reporting estrogen receptor (ER) status or progesterone receptor (PR) status of breast cancer tumors, and studies involving participants with familial adenomatous polyposis (FAP), were summarized to provide additional insights into those meeting the inclusion criteria. FAP is an inherited disorder associated with mutations in the adenomatous polyposis coli (APC) gene and colorectal cancer (CRC). Thus, FAP patients are particularly at risk for developing CRC.

ER+ is the most common breast cancer with 2 out of 3 cases being hormone receptor positive, and most of these ER+. The BReast CAncer susceptibility gene (BRCA) is a genetic mutation predisposing one to an increased risk of breast and/or ovarian cancer. Generally, BRCA 2 tumors are ER+. Given the relationship between ER+ and BRCA 2, it was of interest to see if any studies report associations with BRCA or ER status and n-3 LC-PUFA in blood or diet.

(PUFAs[tiab] OR PUFA[tiab] OR ω-3PUFA[tiab] OR fish oil*[tiab] OR polyunsaturated fatty acid*[tiab] OR “Fatty Acids, Omega-3”[Mesh] OR omega 3 fatty acid*[tiab] OR omega3 fatty acid*[tiab] OR n3 fatty acid*[tiab] OR n 3 fatty acid*[tiab] OR n 3 oil*[tiab] OR n3 oil*[tiab] OR n 3 PUFAs[tiab] OR n3 PUFA[tiab] OR n3 polyunsaturated[tiab] OR Eicosapentaenoic Acid*[tiab] OR Docosahexaenoic Acid*[tiab] OR Docosahexaenate[tiab]) AND (“Neoplasms”[Mesh] OR neoplasm*[tiab] OR neoplastic*[tiab] OR cancer*[tiab] OR carcinoma*[tiab]) AND (genotyp*[tiab] OR “Genes, Neoplasm”[Mesh] OR “Genotype”[Mesh] OR “Mutation”[Mesh] OR “Receptor, ErbB-2”[Mesh] OR “Polymorphism, Genetic”[Mesh] OR “Genetic Markers”[Mesh] OR “Genetic Variation”[Mesh] OR genetic predisposition[tiab] OR tumor gene*[tiab] OR tumour gene*[tiab] OR gene*[tiab] OR genes[tiab] OR genetic[tiab] OR genetics[tiab] OR erbB-2 receptor*[tiab] OR epidermal growth factor receptor 2[tiab] OR phenotype*[tiab] OR “Gene Expression Regulation, Neoplastic”[Mesh]) NOT (animals[mh] NOT humans[mh])

Figure 1. PubMed search string.
3. Results

3.1. Study Selection

The initial database search yielded 1916 distinct citations. An additional 174 citations, identified via other sources, were also included for screening. Eighteen unique studies within 21 publications fit the eligibility criteria within our scoping review (Figure 2). Cancer types include breast cancer \((n = 2)\), gastric cancer \((n = 1)\), exocrine pancreatic cancer \((n = 1)\), chronic lymphocytic leukemia (CLL; \(n = 1)\), prostate cancer (PCA; \(n = 7)\), and colorectal cancer (CRC; \(n = 6)\). Thirteen additional studies, as described above, were added to enhance the understanding of the research topic, i.e., fish intake only \((n = 6)\); studies that involved subjects with FAP \((n = 2)\); and studies that report on the estrogen receptor (ER) or progesterone receptor (PR) status of breast cancer tumors \((n = 5)\) were summarized.

Study characteristics and general results are described in Table 1. Most studies were observational, with case-control studies being the most common study design type \((n = 9)\). Five studies were either randomized controlled trials (RCTs) or post-hoc analyses of RCTs. (See Figure 3) When possible, results of similar studies are synthesized as a group (according to cancer type and then study type). Details regarding genotypes, gene expression pathways and significant statistical results of individual studies can be found in Table 2.

Figure 2. Flow diagram of the search and screen process used in study selection.
| Characteristics | Breast (n = 7) | CRC (n = 12) | Prostate (n = 8) | Other (n = 4) |
|-----------------|---------------|-------------|-----------------|--------------|
| Study Type      | Intervention (n = 1), Prospective cohort (n = 4), nested case-control/case-cohort (n = 2) | RCT (n = 2), Prospective cohort (n = 1), nested case-control/case-cohort (n = 5), case-control (n = 4) | RCT (n = 3), Retrospective cohort (n = 1), nested case-control/case-cohort (n = 5), case-control (n = 3) | Intervention (n = 1), RCT (n = 1), case-control (n = 1), case-case control (n = 1) |
| Year Published (range) | 2003–2017 | 2002–2016 | 2007–2016 | 2007–2014 |
| Geographic Location | Australia (n = 1), China (n = 1), EU (n = 2), Japan (n = 1), USA (n = 2) | EU (n = 4), Singapore (n = 1), UK (n = 3), USA (n = 4) | Mixed (n = 1), Sweden (n = 1), USA (n = 6) | Brazil (n = 1), China (n = 1), Spain (n = 1), USA (n = 1) |
| Total Participants | 11864 | 19629 | 53268 | 663 |
| Average participants per trial (range) | 1695 (43–3885) | 1636 (26–2948) | 1073 * (21–1433) | 165 (20–511) |
| Baseline age range (years) | 27–80 | 16–79 | 35–79 | 18–87 |
| Gender distribution | 100% female | 42–49% female | 50–57% male | 100% male | 28–53% female | 47–72% male |
| Range of Intervention duration | 10 days * | 12 days–6 months | 4 weeks–3 months | 3 days–12 months |
| Duration of follow-up | 4.8–20 years | 1–26 years | NA | NA |
| Mean DHA ± SD, mg/day (range) | 1070 ± 1315 (140–2000) | 200 ± 131 (85–341) | 844 ± 882 (147–1835) | 1800 ± 900 (900–2700) |
| Mean EPA ± SD, mg/day (range) | 80° | 624 ± 942 (15–2000) | 733 ± 566 (72–1098) | 2400 ± 1200 (1200–3600) |
| EPA+DHA, %kcal | 0.19 * | NR | NR | NR |

1 Other includes—gastric, pancreatic, and chronic lymphocytic leukemia; 2 Intervention = non-randomized and/or not placebo controlled; 3 RCT=Randomized controlled trial may also include RCT post-hoc analysis; 4 Mixed consortium = EU, Australia, Malaysia, China, Japan, India, Africa, Canada and USA; 5 Total participants = completed subjects and cases/controls at longest duration of follow-up; 6 only one intervention trial, and, therefore, no range was given; 7 insufficient data to calculate the mean, SD, and range. NA = not applicable NR = data not reported; SD=standard deviation. * Average and range exclude the largest study of n = 45755 subjects.
Figure 3. Number of studies by study design type split by cancer type.
Table 2. Evidence table of included studies.

| Citation                      | Study Type                  | Population Description (N Entered/Completed) | Intervention          | Exposure Assessment | Genotypes/Gene Expression Assessed | Outcomes Assessed | Statistically Significant Results Related to Genotype/Gene Expression and n-3 LC-PUFA Intake/Layers | Interpretation of Results |
|-------------------------------|-----------------------------|----------------------------------------------|------------------------|---------------------|-----------------------------------|------------------|----------------------------------------------------------------------------------|--------------------------|
| Ceschi 2005 [19]; Gago-Dominguez 2004 [11] | Nested case-control | Chinese women: BCa patients: (399/258) Healthy controls: (678/670) | NA | FFQ: marine n-3 & n-6 LC-PUFA intake (quartiles) | CCND1 G870A GSTM1 null-null GSTT1 null-null GSTT1 positive GSTP1 AA GSTP1 AB/BB | BCa risk | Ceschi 2005 Results
CCND1 GA vs. GG genotype: low marine n-3 intake assoc. with decreased risk of BCa (OR = 0.54, 95% CI = 0.32–0.93).
High marine n-3 intake (OR = 0.78, 95% CI = 0.44–1.41) *
CCND1 GA vs. GG genotype with advanced stage BCa: low marine n-3 intake assoc. with decreased risk of BCa (OR = 0.45, 95% CI= 0.24–0.86).
High marine n-3 intake (OR = 0.57 95% CI 0.26–1.26) *
CCND1 GA vs. GG genotype: low marine n-3 and high n-6 intake assoc. with decreased risk of BCa (OR = 0.69 95% CI 0.32–1.49) *
CCND1 GA vs. GG genotype carrying GSTM1-null: low marine n-3 intake assoc. with decreased risk of BCa (OR = 0.19, 95% CI = 0.08–0.43) **
CCND1 GA vs. GG genotype carrying GSTT1-null: low marine n-3 intake assoc. with decreased risk of BCa (OR = 0.33, 95% CI = 0.15–0.73).
High marine n-3 and high n-6 intake (OR = 0.69 95% CI 0.32–1.49) * | Ceschi 2005: Positive (POS) Gago-Dominguez 2004: POS |
Menopausal status did not modify assoc. btn CCND1 status and BCa risk.

**Notes:**
Menopausal status did not modify assoc. btn CCND1 status and BCa risk.

Gago-Dominguez 2004

Results

Post-menopausal women:

GSTT1 null: high (Q2–Q4) vs. low (Q1) marine n-3 intake assoc. with decreased risk of BCa (OR 0.29, 95% CI = 0.11–0.73)

*Note: borderline statistically significant*

GSTP1 AB/BB: high (Q2–Q4) vs. low (Q1) marine n-3 intake assoc. with decreased risk of BCa (OR 0.49, 95% CI = 0.26–0.93)

GSTM1 null-null and GSTP1 AB/BB: high (Q2–Q4) vs. low (Q1) marine n-3 intake assoc. with decreased risk of BCa (OR 0.36, 95% CI = 0.14–0.94)

GSTT1 null and GSTP1 AB/BB: high (Q2–Q4) vs. low (Q1) marine n-3 intake assoc. with decreased risk of BCa (OR 0.26, 95% CI = 0.08–0.78)

Pre-menopausal women:

No evidence of risk modification by genotype or gene-diet interaction.

Intervention trial, non-randomized, not placebo controlled

BRCA1/2 (12/11)

Familial history of BCa (12/12)

Sporadic BCa (10/10)

Healthy Controls (11/10)

DHA 2g/day for 10 days

RBC: EPA, DHA, omega-3 Index

FFQ: seafood intake

BRCA1

BRCA2

Timepoints:
Baseline, day 10
DHA bioavailability

Not Applicable (NA)

Molfino 2017

[20]

Intervention trial, non-randomized, not placebo controlled

BRCA1/2 (12/11)

Familial history of BCa (12/12)

Sporadic BCa (10/10)

Healthy Controls (11/10)

DHA 2g/day for 10 days

RBC: EPA, DHA, omega-3 Index

FFQ: seafood intake

BRCA1

BRCA2

Timepoints:
Baseline, day 10
DHA bioavailability

BRCA1 or BRCA 2 gene mutation predicted higher DHA levels in RBC membranes vs. healthy controls post-supplementation ($\beta$ coefficient = 0.30; 95% CI = 0.05–0.55; $p = 0.02$)

Not Applicable (NA)
| Study | Type | Design | Participants | Exposure | Follow-up | Outcome | ER+ BCa: | ER− BCa: |
|-------|------|--------|--------------|----------|-----------|---------|---------|---------|
| Stripp 2003 [21] | Prospective cohort study | 23,693 post-menopausal women resulting in 424 cases (303 ER+ cases; 91 ER− cases; 30 cases unknown) | N/A | FFQ: total fish/lean fish/fatty fish intake; (g/day; quartiles) | Follow-up: median length of 4.8 years | BCa risk | high total fish intake assoc. with increased rate of ER+ BCa (adjusted IRR per additional 25 g of mean daily intake of fish: 1.14; 95% CI = 1.03–1.26) | NS interaction |
| Bassett 2016 [22] | Case-cohort | BCa cases (571/470) healthy controls (2492/2021) | NA | %PPL fatty acids: DHA, EPA, total n-3 LC-PUFA (quintiles) FFQ: DHA, EPA (g/day; quintiles) | BCa risk in relation to PPL and fatty acid intake stratified by ER+ or PR+ status | High EPA dietary intake (Q5 vs. Q1) assoc. with decreased risk of ER+ BCa (HR = 0.82; 95% CI = 0.72–0.94; p = 0.004); high DHA dietary intake (Q5 vs. Q1) assoc. with decreased risk of ER+ BCa (HR = 0.84; 95% CI = 0.73–0.96; p = 0.01) | ER−/PR− BCa: NS interaction |
| Kim 2006 [23] | Prospective cohort | 121701 (80375 completed) postmenopausal women resulting in 3537 cases | N/A | FFQ: n-3 LC-PUFA (% of energy) | Follow-up: 20 years | BCa risk | ER/PR status and n-3 LC-PUFA intake: NS | NULL |
| Kiyabu 2015 [24] | Prospective cohort | 55541 (38234 completed) Japanese women aged 45–74 resulting in 556 cases of BCa | N/A | FFQ: total n-3, DHA, EPA, fish, n-3 LC-PUFA-rich fish intake (g/day; quartiles) | Follow-up: 14.1 years | BCa risk | ER+ PR+ BCa and fish or n-3 LC-PUFA-rich fish intake: NS | POS |

**Breast Cancer Studies — Fish Only + ER/PR Status (n = 1)**

**Breast Cancer Studies — ER/PR Status (n = 4)**
| Study | Design | Population | Methodology | ER/PR status | Follow-up | Findings |
|-------|--------|------------|-------------|--------------|-----------|----------|
| Park 2011 [25] | Prospective Cohort | 99800 (85089 completed) post-menopausal women resulting in 3885 cases of invasive BCa | FFQ: EPA, DHA (g/1000 kcal; quintiles) | ER/PR status | Follow-up: 12.4 years BCa risk | Decreased risk btn Q2 vs. Q1 (multivariable-adjusted HR Q2 vs. Q1 = 0.47; 95% CI = 0.25–0.89; p trend 0.47). Note: EPA was overall protective but only statistically significant at Q2. |

### Included Colorectal Cancer Studies (n = 6 of 7 Reports)

| Study | Design | Population | Methodology | Findings |
|-------|--------|------------|-------------|----------|
| Habermann 2013 [26] | Case-control | Colon cancer patients (1574/1543) Rectal cancer patients (791/712) Healthy controls to colon cancer cases (1970/1900) and rectal cancer cases (999/912) | FFQ (CARDIA diet history questionnaire): EPA, DHA and total PUFA and total n-3 LC-PUFA intake (tertiles) | 107 candidate polymorphisms and tagSNPs within: PTGS1 PTGS2 ALOX12 ALOX5 ALOX15 FLAP | CRC risk | PTGS1 rs10306110 (−1053 A > G) variant genotypes (AG/GG): low DHA intake assoc. with increased CRC risk (OR = 1.62, 95% CI = 1.14–2.30), adj. p-interaction 0.003, Bonferroni adj. p = 0.06); low EPA intake assoc. with increased CRC risk (OR = 1.56, 95% CI = 1.09–2.22, p-interaction 0.006, Bonferroni adj. p = 0.10) | ALOX15 rs11568131 (10,339 C > T) wild type (GG genotype): high EPA intake assoc. with decreased CRC risk (OR = 0.80, 95% CI = 0.65–0.98, p- | POS |
Kantor 2014 [27] Nested case-control CRC patients (260/260) Healthy controls (250/250) NA

**FFQ:** Average 10-year fish oil supplement use (none, low, high); dark fish intake, dietary and total EPA and DHA (quartiles)

- rs6691170(1q41)
- rs6687758(1q41)
- rs10936599(3q26.2)
- rs16892766(8q23.3)
- rs6983267(8q24.21)
- rs10795688(10p14)
- rs3802842(11q23.1)
- rs11169552(12q13.13)
- rs7136702(12q13.13)
- rs4444235(14q22.2)
- rs4779584(15q13.3)
- rs9929218(16q22.1)
- rs4939827(18q21.1)
- rs10411210(19q13.1)
- rs961253(20p12.3)
- rs4925386(20q13.33)

**Note:** A genetic risk score was created by a tally of risk alleles present in the above 16 SNPs located within identified CRC susceptibility loci.

**CRC risk**

interaction 0.02; Bonferroni adj $p = 0.36$.

**Overall genetic risk and dark fish intake: significant interaction ($p = 0.009$)**

**Overall genetic risk and EPA + DHA intake: significant interaction ($p = 0.02$)**

**Lowest tertile of genetic risk:** increasing dark fish intake assoc. with decreased CRC risk (Q4 OR = 0.13, 95% CI = 0.04–0.48); increasing total EPA + DHA intake assoc. with decreased CRC risk (Q4 OR = 0.23, 95% CI = 0.07–0.78)

**Mid tertile of genetic risk:** increasing dark fish intake assoc. with decreased CRC risk (Q4 OR = 0.14, 95% CI = 0.04–0.53); with increasing total EPA + DHA intake assoc. with decreased CRC risk (Q4 OR = 0.43, 95% CI = 0.21–1.41)

**Highest tertile of genetic risk:** increasing dark fish intake assoc. with increased CRC risk (Q4 OR = 1.59, 95% CI = 0.51–4.97); with increasing total EPA + DHA intake assoc. with increased CRC risk (Q4 OR = 5.79, 95% CI = 1.79–18.7)

When the genetic risk score was limited to 6 SNPs assoc. with the TGF-β pathway, no interaction
was observed (results not shown)

**Song 2015 Results**

CIMP-low/negative status, high microsatellite instability CRC tumor:
- increasing marine n-3 LC-PUFA intake assoc. with decreased CRC risk (Q1 vs. Q4 intake HR 0.28; 95% CI = 0.12–0.66; *p*-trend = 0.02)

**Song 2016 Results**

FOXP3+ T-cell high CRC tumors:
- higher marine n-3 LC-PUFA intake assoc. with decreased CRC risk (*p* for heterogeneity = 0.006; regardless of MSI status)

| Year | Cohort | Participants | CRC cases | Specimens | MSI status | MSIR | Follow-up | CRC risk |
|------|--------|--------------|-----------|-----------|------------|------|-----------|----------|
| Song 2015 | Prospective cohort | (173,230/NR) resulting in 2501 | 1125 specimens were observed for MSI status | None | CIMP, CRCNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROGI, RUNX3, SOCS BRAF (codon 600): Wild-type, Mutated T-cells classified as either high or low-level infiltrate in CRC tumor tissue: CD3+, CD8+, CD45RO (PTPRC)+, or FOXP3+ | 24-26 years | MSI status |

Follow-up: 24-26 years

**CRC risk**

| Group | HR (95% CI) | *p* value |
|-------|-------------|-----------|
| Q1 vs. Q4 intake | 0.28 (0.12–0.66) | <0.001 |

**Song 2016 Participants**

(173,229/125,172) resulting in 2504 CRC cases of which 614 specimens were observed for T-cell infiltration in the tumor microenvironment

**Follow-up:**

24-26 years

**CRC risk**

| Group | HR (95% CI) | *p* value |
|-------|-------------|-----------|
| ≥0.35 g/day vs. <0.15 g/day | FOXP3+ T-cell high CRC tumors: higher marine n-3 LC-PUFA intake assoc. with decreased CRC risk (multivariable HR = 0.57, 95% CI = 0.40–0.81, *p* for trend < 0.001.) |
| Q3 and Q4 vs. Q1 | FOXP3+ T-cell high CRC tumors: higher EPA intake assoc. with decreased CRC risk (multivariable HR = 0.67, 95% CI = 0.49–0.93 and multivariable HR = 0.61, 95% CI = 0.44–0.86 respectively, *p* for trend = 0.003) |
| Q3 and Q4 vs. Q1 | FOXP3+ T-cell high CRC tumors: higher DHA intake assoc. with decreased CRC risk (multivariable HR = 0.58, 95% CI = 0.41–0.80 and multivariable HR = 0.65, 95% CI = 0.46–0.90 respectively, *p* for trend = 0.003). |
| Study                          | Design/Case-Control | Group Description                                                                 | FFQ/Dietary Intake                      | Genotypes/Genetic Factors                                      | Outcome                        |
|-------------------------------|---------------------|-----------------------------------------------------------------------------------|-----------------------------------------|---------------------------------------------------------------|--------------------------------|
| Stern 2009 [30]               | Nested case-control | Colon cancer patients (180/180) Rectal cancer patients (131/130) Healthy controls (1181/1176) | FFQ: total n-3 LC-PUFA and marine n-3 intake (low and high intake) | XRCC1: Arg194Trp (rs1799782), Arg399Gln (rs25487) OGG1: Ser326Cys (rs1052133) PARP: Val762Ala (rs1136410), Lys940Arg (rs3219145) XPD: Asp312Asn (rs1799793), Lys751Gln (rs13181) | CRC risk                       |
| Theodoratou 2008 [31]         | Case-control        | Patients with adenocarcinoma of colorectum (2799/1656) Healthy controls (2749/2292) | FFQ: EPA, DHA and n-3 LC-PUFA intake (tertiles) | APC 1822, APC 1317 | CRC risk                       |
| Volpato 2016 [32]             | RCT post-hoc analysis | Clinical samples from RCT of patients undergoing liver surgery for CRC liver metastasis (CRCLM) | FFQ: n-3 LC-PUFA levels at baseline, before surgery and 6 weeks after discharge. CRCLM tissue: EPA levels | CCL2 plasma levels Genome-wide transcriptional profiling of tumors | Timepoints: pre-treatment, post-treatment CCL2 plasma and tissue levels | Plasma CCL2 levels with EPA intake vs. Placebo post-treatment: decreased CCL2 levels (p = 0.04) before liver resection. Reduction in plasma CCL2 following EPA POS |
EPA 2g/day (29/29)
Placebo (26/26)

**treatment predicted improved disease-free survival (HR 0.32; 95% CI = 0.05–0.51, p = 0.003).** Lack of 'CCL2 response' to EPA (i.e., increase or no change in CCL2 following treatment) was assoc. with a specific CRCLM gene expression signature. The authors concluded that reduction in plasma CCL2 in patients with CRCLM treated with EPA predicts better clinical outcome and a specific tumor gene expression profile.

| Study | Design | Cohort | N/A | FFQ: fish intake (g/day; tertiles) | APC gene mutation status | CRC risk | APC gene mutation or hMLH1 expression and fish intake levels: NS. |
|-------|--------|--------|-----|----------------------------------|-------------------------|----------|---------------------------------------------------------------|
| Andersen 2013 [33] | Case-cohort | CRC patients (970/970) Healthy controls (1897/1789) | N/A | IL10 C-592A (rs1800872) C-rs3024505-T IL1b C-3737T (rs4848306) G-1464C (rs1143623) T-31C (rs1143627) PTGS2 (encoding COX-2) A-1195G (rs689466) G-765C (rs204177) T8473C (rs5275) | CRC risk | IL10 rs3024505 homozygous wild-type carriers (CC) vs. variant carrier (CT-TT): per 25 g fish/day assoc. with decreased CRC risk (CC adjusted IRR = 0.90; 95% CI = 0.82–0.99) vs. CT-TT IRR = 1.08; 95% CI = 0.94–1.24, p-interaction = 0.0065. |
| Luchtenborg 2005 [34] | Case-cohort | CRC patients (929/588) Healthy controls (3346/2948) | N/A | APC gene mutation status hMLH1 expression | CRC risk | APC gene mutation or hMLH1 expression and fish intake levels: NS. |
| Slattery 2010 [35] | Case-control | Rectal cancer patients with primary tumor in the rectosigmoid junction or rectum (1505/750) Healthy controls (1838/1250) | None | TP53 gene mutations: codons 175, 245, 248, 257, 283 K-RAS2 mutations: codons 12 and 13 CIMP markers (phenotype): MINT1, MINT2, MINT31, CDKN2A (p16), MLH1 | Risk of having genetic rectal tumor mutations | CIMP+, TP53 or KRAS2 gene mutation tumors and fish intake levels: NS Note: Participants carrying CIMP with higher levels of n-3 LC-PUFA were assoc. with a twofold increased risk of a CIMP+ tumor however, type of n-3 LC-PUFA was not defined |
| Tiemersma 2002 [36] | Nested case-control | CRC patients (NR/102) | N/A | NAT1 and NAT2 GSTM1 genotype | CRC risk | NAT1, NAT2 or GSTM1 with fish intake: NS |

**Colorectal Cancer Studies—Fish Only (n = 4)**

**Andersen 2013 [33]**
Case-cohort
CRC patients (970/970)
Healthy controls (1897/1789)
FFQ: fish intake (g/day; tertiles)

**Luchtenborg 2005 [34]**
Case-cohort
CRC patients (929/588)
Healthy controls (3346/2948)
FFQ: fish intake (g/day; quartiles)

**Slattery 2010 [35]**
Case-control
Rectal cancer patients with primary tumor in the rectosigmoid junction or rectum (1505/750)
Healthy controls (1838/1250)
FFQ (CARDIA diet history questionnaire): total n-3 LC-PUFA and fish intake (tertiles)

**Tiemersma 2002 [36]**
Nested case-control
CRC patients (NR/102)
FFQ: fish intake (servings/month; 0–1, 1–4, 4+ servings)
### Healthy controls (NR/537)

### Colorectal Cancer Studies — FAP Studies (n = 2)

| Study             | Design | Healthy Controls | FAP Patients | FAP Controls | Trial Design | FFQ (FAP patients) | PPL in FAP patients vs. healthy controls | DHA PPL levels (weight %): lower in controls vs. FAP patients (difference: -5.26, 95% CI = -6.25 to -4.28, p ≤ 0.0001) | DHA PPL levels (mg/L) lower in controls vs. FAP patients (difference: -62.5, 95% CI = -78.14 to -46.83, p ≤ 0.0001) |
|-------------------|--------|------------------|--------------|--------------|--------------|---------------------|------------------------------------------|----------------------------------------------------------------------------------|
| Almendingen 2006 [37] | Case-control | NR/537 | 38/NR | 160/NR | FFQ (FAP patients) and 14-day diet diaries; (controls): total n-3 LC-PUFA, DHA, EPA intake (% total energy) Serum PPL: total n-3 LC-PUFA, DHA, EPA | FAP | NA |

### West 2010 [38] RCT

| Study             | Design | Patients with FAP undergoing endoscopic surveillance of their retained rectum post-colectomy (58/55) | 2g EPA-FFA/day vs. placebo for 6 months | fatty acid content of rectal mucosa | Number and size of polyps | Global rectal polyp burden | Mucosal fatty acid content | EPA-FFA vs. Placebo at 6 months: Larger decrease in number of polyps: (difference btn groups -1.06; 95% CI = -1.78 to -0.35; p = 0.006) Larger % change in # of polyps: (difference btn groups -22.4%; 95% CI = -39.6 to -5.1; p = 0.012) Larger % decrease in polyp diameters: (difference btn groups -29.8%, 95% CI: -56.1 to -3.6%, p = 0.027) Global polyp burden: EPA-FFA group remained stable while placebo group worsened (difference btn groups 0.42, CI = 0.10-0.75, p = 0.011) |
|-------------------|--------|--------------------------------------------------|----------------------------------------|------------------------------------|--------------------------|-------------------------------|-----------------------------------|----------------------------------------------------------------------------------|
| Chan 2011 [39]; Magbanua 2011 [40] | RCT | Men with low-burden PCA randomized to: Fish oil (27/21) Lycopene (20/22) | EPA 1098mg + DHA 549mg/day for 3 months Vs. FFQ | Chan 2011 COX-2, IGF-I, IGF-IR gene expression in prostate tissue Chan 2011: Changes in normal tissue | Chan 2011 Results: Fish oil vs. placebo: NS change in IGF-1 and COX-2 gene expression in subjects | Chan 2011 Results |

### Included Prostate Cancer Studies (n = 7 of 8 Reports)

- **Chan 2011 [39]**
  - COX-2, IGF-I, IGF-IR gene expression in prostate tissue
- **Chan 2011 Results**
  - Fish oil vs. placebo: NS change in IGF-1 and COX-2 gene expression in subjects

- **Magbanua 2011 [40]**
  - Changes in normal tissue
- **Magbanua 2011 Results**
  - NULL
Olive oil placebo (28/26)  Lycopene 30mg/day for 3 months Vs. Olive oil placebo for 3 months

Gene expression pathways:
- Alanine and Aspartate Metabolism
- Aminoacyl-tRNA Biosynthesis
- Androgen and Estrogen Metabolism
- Apoptosis Signaling
- Arachidonic Acid Metabolism
- Axonal Guidance Signaling
- Biosynthesis of Steroids Butanoate Metabolism
- C21-Steroid Hormone Metabolism
- Caveolar-mediated Endocytosis
- CD27 Signaling in Lymphocytes
- Cell Cycle: G1/S Checkpoint Regulation
- Ceramide Signaling
- Cyanobioic Acid Metabolism
- DHA Signaling
- Endoplasmic Reticulum Stress Pathway
- GABA Receptor Signaling
- Galactose Metabolism
- Glutathione Metabolism
- Glycosaminoglycan Degradation
- Glycosphingolipid Biosynthesis–Ganglioseries
- Hepatic Cholestasis
- Inositol Metabolism
- Insulin Receptor Signaling
- LPS/IL-1 Mediated Inhibition of RXR Function

gene expression biopsies in IGF-1 and in COX-2

Magbanua 2011

Gene expression pathways modulated by interventions

NS changes (after adjustment) in individual gene expression were detected in normal prostate tissue after fish oil supplementation. Canonical pathway analysis *, however, suggests statistically significant modulation of the following pathways in subjects taking fish oil supplementation vs. placebo at 3 months:
- Arachidonic acid metabolism ($p = 0.0135$)
- Nuclear factor (erythroid derived-2) factor 2 or Nrf2-mediated oxidative stress response ($p = 0.0123$)
- Glutathione metabolism ($p = 0.0204$)
- Cyanobioic Acid Metabolism ($p = 0.0209$)
- Metabolism of Xenobiotics by Cytochrome P450 ($p = 0.0316$)
- Alanine and Aspartate Metabolism ($p = 0.0324$)
- GABA Receptor Signaling ($p = 0.0457$)
- Nitrogen Metabolism ($p = 0.0435$)

* For unadjusted, statistically significant changes in individual gene expression please consult original publication.
| Study               | Design                        | Participants                                                                 | Outcomes                                                                 |
|---------------------|-------------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Cheng 2013 [41]     | Nested case-control           | Current/former smokers with workplace asbestos exposure within last 15 years: PCA patients (724/641) Healthy controls (1474/1398) | Metabolism of Xenobiotics by Cytochrome P450 Methane Metabolism Methionine Metabolism N-Glycan Biosynthesis N-Glycan Degradation Nitrogen Metabolism Nrf2-mediated Oxidative Stress Response Oxidative Phosphorylation Pantothenate and CoA Biosynthesis PXR/RXR Activation Selenoamino Acid Metabolism Sonic Hedgehog Signaling Sphingolipid Metabolism Stilbene, Coumarine and Lignin Biosynthesis Tryptophan Metabolism Ubiquinone Biosynthesis PCA risk MPO G-463A (rs2333227) | PCA risk MPO GA/AA vs. GG genotype: low EPA + DHA (Q1) assoc. with increased risk of aggressive PCA (OR = 1.97, 95% CI = 1.07–3.63). |
| Cui 2016 [42]       | Retrospective Cohort          | Specimens from PCA patients undergoing radical prostatectomy (60/60)          | Metabolism of Xenobiotics by Cytochrome P450 Methane Metabolism Methionine Metabolism N-Glycan Biosynthesis N-Glycan Degradation Nitrogen Metabolism Nrf2-mediated Oxidative Stress Response Oxidative Phosphorylation Pantothenate and CoA Biosynthesis PXR/RXR Activation Selenoamino Acid Metabolism Sonic Hedgehog Signaling Sphingolipid Metabolism Stilbene, Coumarine and Lignin Biosynthesis Tryptophan Metabolism Ubiquinone Biosynthesis | FADS rs 174537 GG vs. TT: lower PCA tissue DHA levels assoc. with TT genotype (median 2.11 %total fatty acids, IQR = 1.79–3, mean difference = -0.75, p = 0.03) |
**Table 1: Nutrient Intake and PCA Risk**

| Study Year | Study Design | Study Population | FFQ Details | COX-2 Gene Details | Timepoints | CCP Score Details | Notes |
|------------|--------------|------------------|--------------|--------------------|------------|-------------------|-------|
| Fradet 2009 [15] | Case-control | Aggressive PCA patients (506/466) Healthy controls (506/478) | FFQ: EPA, DHA, total n-3 LC-PUFA (quartiles); dark/white/fried fish, shellfish, tuna intake (tertiles) | COX-2 rs4648310 AA: increasing n-3 LC-PUFA intake assoc. with decreased PCA risk (OR = 0.61, 95% CI = 0.47–0.81; p trend 0.006) | PCA risk | COX-2 rs4648310 (+8897 AG or GG): low n-3 LC-PUFA intake assoc. with increased PCA risk (OR = 5.49; 95% CI = 1.80–16.7) and reversed by increasing n-3 LC-PUFA intake (OR = 0.42; 95% CI = 0.13–1.37) | POS |
| Galet 2014 [43] | RCT post-hoc analysis | PCA patients 4–6 weeks prior to radical prostatectomy randomized to: Low-fat diet (29/27) Western diet (26/21) | Low-fat diet plus EPA 1000mg + DHA 1835mg/day for 4–6 weeks vs. Western Diet for 4–6 weeks | CCP score: low-fat fish oil resulted in decreased PCA tissue CCP score post-intervention vs. western diet (p = 0.03) | CCP score | CCP score: low-fat fish oil resulted in decreased PCA tissue CCP score post-intervention vs. western diet (p = 0.03) | POS |
| Hedlin 2006 [16] | Case-control | PCA patients (1499/1378) Healthy controls (1130/782) | FFQ: n-3 LC-PUFA, EPA+DHA intake (quartiles); various types of fish intake (tertiles) | COX-2 gene (rs5275: 16365 T/C): salmon-type fish intake 1x/week or more vs. never assoc. with decreased PCA risk (OR = 0.28, 95% CI = 0.18–0.45; p trend < 0.01). All genotypes and intake of white fish, shellfish, herring/mackerel or EPA/DHA fatty acids: NS | PCA risk | EPA/DHA: NULL Salmon intake: POS | POS |
| Khankari 2016 [44] | Case-control | PCA patients (NR/22721) Healthy controls (NR/23034) Total participants (48056/45755) | Predicted plasma% of total fatty acids directly genotyped: rs780094, rs2236212, rs174538 imputed: rs734398, rs3798713, rs1074011, rs174547 | Predicted plasma% of total fatty acids directly genotyped: rs780094, rs2236212, rs174538 imputed: rs734398, rs3798713, rs1074011, rs174547 | PCA risk | When using the weighted PUFA-specific polygenic risk score (WP5S) no overall association was observed b/w the genetically-predicted n-3 | NEG |
**Prostate Cancer Studies—Fish Only (n = 1)**

| Catsburg 2012 [45] | Case-control | Localized and advanced PCA patients (1800/1433) | Healthy controls (1139/760) | FFQ: dark and white fish intake (never, low, high intake) | PCA risk |
|-------------------|---------------|-----------------------------------------------|----------------------------|-------------------------------------------------|---------|
|                   |               |                                               |                            | N/A                                             |         |

**Included Other Cancer Studies (n = 3)**

| Fahrmann 2013 [46] | Uncontrolled non-randomized intervention pilot study | Patients with CLL in the early stages (Rai Stage 0–1) (15/15) Healthy patients to establish normal values for NFκB activation in lymphocytes (no intervention given; n = 5) | Monthly escalating dosages up to 12 months: EPA 1200mg + DHA 900mg/day EPA 2400mg + DHA 1800mg/day | Plasma fatty acids | NF-κB pathway Expression of 32 genes in lymphocytes Note: NFκB may play a key role in controlling apoptosis and disease progression in hematologic malignancies with previous evidence showing inhibition of NFκB activity in lymphocytes in CLL patients. | Timepoints: baseline, 2.4g, 4.8g, 7.2g and 3 months post-intervention. Suppression of NF-κB activity in lymphocytes in CLL patients. |
|-------------------|-----------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-----------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
|                   |                                                     |                                                                                                 |                                                                                                 |                 |                                                                                                 |                                                                                                 |

LC-PUFA evaluated and PCA risk. However, when stratified by age, modest increases in PCA risk were observed for EPA (OR = 1.04, 95% CI = 1.01–1.06) among men >62 years of age.

PTGS2 765 G/C: high white fish intake vs. no/rare white fish intake assoc. with increased advanced PCA risk (adjusted OR = 1.85; 95% CI 1.19–2.89), stronger assoc. with well-done white fish (adjusted OR = 2.17 (1.05–4.48), NS after Bonferroni adjustment.

PTGS2 765 C/C: high white fish intake vs. no/rare white fish intake assoc. with >3-fold increased advanced PCA risk (adjusted OR = 3.56; 95% CI = 1.61–7.88).

PTGS2 765 G/G: high dark fish intake assoc. with decreased advanced PCA risk (adjusted OR = 0.53; 95% CI 0.35–0.80), NS after Bonferroni adjustment, data not shown.

White Fish: NEG
Dark Fish: POS
| Study                  | Design  | Participants                                      | Intervention                                      | NFκB activation in vitro resulted in apoptosis of the malignant cells. | Doxorubicin sensitivity, mRNA lymphocyte expression | intervention vs. baseline (p = 0.040) 7.2g n-3 LC-PUFA/day intake returned NFκB activity to levels comparable to control patients (mean ± SD: 87,138 ± 79,040 NFκB luminescence units/μg protein). mRNA abundance of any genes in patients with higher baseline NF-kB activation levels: significant decrease in abundance of 16 of the 31 identified mRNA genes vs. baseline NF-κB activity in patients with lower baseline NF-κB activation levels: NS. However, 7.2g n-3 LC-PUFA/day returned NF-κB activity to levels comparable to control patients. mRNA abundance of any genes in patients with lower baseline NF-kB activation levels: NS. |
|------------------------|---------|---------------------------------------------------|--------------------------------------------------|---------------------------------------------------------------|------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Cury-Boaventura 2012 [47] | RCT     | Surgical patients with gastric or colon cancer (25/25) | Omegavenos® (pure fish oil; 12/NR) Lipovenos® (medium/long-chain triglycerides and soybean oil; 13/NR) Both given 0.2 g/kg body weight 10% for 3 days post-surgery | 800 genes related to inflammation, of which 108 were involved in cell death detected by 16-Assay Bioarray Hybridization and Detection | Timepoints: Baseline (t0), after infusion (t1), 3rd post-operative day (t2) leukocyte death, cell viability, apoptotic markers, and expression of genes assoc. with cell death Up regulation expression of genes with fish oil emulsion: - 3 genes related to cell death: TNF receptor–assoc. factor 3 [TRAF3]; BCL2-assoc. anathogene 4 [BAG4]; non-metastatic cells 1 [NME1] protein [NM23A] | POS                                                                 |

**EPA 3600mg + DHA 2700mg/day**
- 2 genes related to cell proliferation: macrophage colony-stimulating factor 1 [CSF1]; granulocyte-macrophage colony-stimulating factor 2 [CSF2])

Down regulation expression of genes with fish oil emulsion:

- 2 genes related to cell death: bifunctional apoptosis regulator [BFAR]; growth arrest and DNA damage-inducible alpha [GADD45A]

### Morales 2007 [48]

| Case-case | Pancreatic cancer patients with K-ras mutation (94/83) | FFQ: n-3 intake (tertiles); fish and shellfish (low, medium, high) | K-ras gene | Risk of K-ras mutation |
|-----------|---------------------------------------------------|---------------------------------------------------------------|-------------|-----------------------|
| None      |                                                   |                                                               |             |                       |

K-ras mutated vs. without K-ras mutation:

- fish/seafod intake: NS; high n-3 fatty acids intake assoc. with decreased risk of K-ras mutation (OR = 0.19; 95% CI = 0.05–0.81; p = 0.024)

Note: type of n-3 PUFA undefined.

### Huang 2014 [49]

| Case-control | Gastric cancer patients (217/217) Healthy controls (294/294) | FFQ: seafood intake (servings/week) | TLR4: rs10116253 (CC/CT) genotype: seafood intake assoc. with decreased risk gastric cancer (<1/week OR = 0.60, 95% CI 0.38–0.94; >1 time/week OR = 0.27, 95% CI = 0.11–0.65), NS interaction btn polymorphisms |
|---------------|----------------------------------------------------------------|------------------------------------|-------------------------------------------------|
| NA            |                                                              | TLR4: rs10116253 (TT, TC, CC, TC/CC) rs1927911 (CC, CT, TT, CT/TT) | Gastric cancer risk (≥1 time/week) assoc. with reduced gastric cancer risk (OR = 0.09, 95% CI = 0.03– |

Other Cancer Studies — Seafood Only (n = 1)

- TLR4 rs10116253 CC/CT genotype: seafood intake assoc. with decreased risk gastric cancer (<1/week OR = 0.60, 95% CI 0.38–0.94; >1 time/week OR = 0.27, 95% CI = 0.11–0.65), NS interaction btn polymorphisms

POS
* High marine n-3 intake associated with decreased risk but NS ** When analysis was restricted to subjects with both low activity GST genotypes and low n-3 or high n-6 intake authors report “sparse data and unstable OR estimates” (sample sizes not reported). Abbreviations: APC = adenomatous polyposis coli (gene); ALOX = arachidonate 5-lipoxygenase; assoc. = associated; btn = between; BCa = breast cancer; BRAF = B-Raf proto-oncogene; BRCA = BReast CAncer susceptibility (gene); CCL2 = C-C motif ligand 2 (chemokine); CCND1 = Cyclin D1 (gene); CCP = cell-cycle progression; CI = confidence interval; CIMP = CpG island methylator phenotype; CL = chronic lymphocytic leukemia; COX-2 = cyclooxygenase-2; CRC = colorectal cancer; CYP = cytochrome; DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; ER = estrogen receptor; ER+ = estrogen receptor positive; ER− = estrogen receptor negative; FADS = fatty acid desaturase; FAP = familial adenomatous polyposis; FFQ = food frequency questionnaire; FLAP = 5-lipoxygenase-activating protein; g = grams; GST = glutathione S-transferases (gene); HR = hazard ratio; IGF = insulin-like growth factor; IQR: interquartile range; IRR: incidence rate ratio; mg = milligrams; MIXED = results were both in favor and not in favor of DHA or EPA intake or higher levels of DHA or EPA and risk of cancer depending on the genetic mutations or gene expression pathways; MPO = myeloperoxidase; MSI = microsatellite instability; NAT = N-acetyltransferases; n-3 LC-PUFA = omega-3 long-chain polyunsaturated fatty acids; NEG = results not in favor of DHA or EPA intake or higher levels of DHA or EPA and risk of cancer with certain genetic mutations or gene expression pathways; Nf-KB = Nuclear factor Kappa B; NR: not reported; NS = no statistically significant results; OGG1 = 8-Oxoguanine glycosylase; OR = odds ratio; PARP = poly ADP ribose polymerase (gene); PCA = prostate cancer; POS: results in favor of DHA or EPA intake or higher levels of DHA or EPA and risk of cancer with certain genetic mutations or gene expression pathways; PPL = plasma phospholipid(s); PR = progesterone receptor; PR+ = progesterone receptor positive; PR− = progesterone receptor negative; PTGS1 = prostaglandin-endoperoxide synthase 1 (gene); PTGS2 = prostaglandin-endoperoxide synthase 2 (gene); PUFA = polyunsaturated fatty acids; Q = quartile or quintile; RBC = red blood cell; RR = risk ratio; SNP = single nucleotide polymorphisms; tagSNP = a single nucleotide polymorphism used to tag a particular haplotype within the genome; TGF-β = transforming growth factor-beta; UGT = UDP Glucuronosyltransferase; XPD = XRCC1 = X-ray repair cross-complementing protein 1.
3.2. Breast Cancer Studies

Two breast cancer studies within three reports met the inclusion criteria (see Table 2). A nested case-controlled study reported within two publications involving 399 breast cancer cases and 678 healthy controls reported no overall association between glutathione S-transferases (GST) genotypes and breast cancer risk. However, in post-menopausal women, differences in risk between high- and low-activity GST genotypes when stratifying risk by marine n-3 fatty acid intake was shown. Specifically, post-menopausal women with specific GST genotypes and consuming ≤200 mg marine n-3 fatty acids daily exhibited ~50% decreased cancer risk versus those consuming higher intakes of marine n-3 fatty acids [11]. In a kin paper, Ceschi et al. (2005), found that the heterozygous Cyclin D1 (CCND1) GA genotype decreased risk in all subjects compared to the GG genotype but the association was limited to women with high n-6 fatty acid intake or low marine n-3 intake or a total lack of certain GST genes. The effect was stronger in advanced disease [19].

Molfino et al. (2017) conducted an interventional, non-randomized, not placebo-controlled trial investigating DHA incorporation into red blood cells (RBC) after 2g DHA supplementation for 10 days in 11 healthy controls and 34 breast cancer patients. Statistically higher DHA incorporation in RBC membranes of BRCA 1 and 2 mutation carriers versus healthy controls was found [20]. Earlier, in vitro data in breast cancer cell lines demonstrated an increase in BRCA1 and BRCA2 mRNA expressions with DHA treatment, suggesting a transcriptional or post-transcriptional regulation of these genes by DHA [50]. Preclinical data also showed that DHA treatment increases BRCA1 protein level by 60% compared to an unsupplemented group and significantly reduced the incidence of breast cancer, potentially signifying a protective effect [51].

Additional Breast Cancer Studies—ER/PR Status

Results for an additional five studies that reported on ER/PR status are summarized (see Table 2). Four of the studies were prospective cohort studies involving 300,735 women resulting in 8402 breast cancer cases [21,23–25]. Two of these studies found a positive inverse association between n-3 LC-PUFA or fish intake, ER+ / PR status and decreased breast cancer risk [23–25]. Stripp et al. (2003) found high total fish intake increased the risk of ER+ breast cancer [21], although individual fatty acid intakes were not measured.

Bassett et al. (2016) conducted a case-cohort study involving 571 breast cancer cases and 2492 healthy controls. High dietary intake of both EPA and DHA was also associated with decreased risk of ER+ breast cancer [22].

3.3. Colorectal Cancer Studies

Six studies within seven reports involving CRC fit the inclusion criteria as shown in Table 2. There were four case-controlled or nested case-controlled studies involving 5905 CRC cases and 5311 healthy controls [26,27,30,31]. A study by Habermann et al. (2013) found that carriers of prostaglandin-endoperoxide synthase 1 (PTGS1) rs10306110 (−1053 A>G) with low DHA intake resulted in an increased risk of colon cancer [26]. Another study by Theodoratou et al. (2008) found that subjects with wild-type and heterozygous APC 1822 and low intake levels of n-3 LC-PUFA had an increased CRC risk, while subjects with homozygous APC 1822 (TT) and low levels of n-3 LC-PUFA intake had a decreased CRC risk [31]. Stern et al. (2003) found that subjects with the poly ADP ribose polymerase (PARP) gene (rs1136410) and high marine n-3 LC-PUFA intake had an increased CRC risk. Further analysis revealed that this PARP gene modified associations between marine n-3 LC-PUFA and CRC risk only amongst rectal cases [30]. Kantor et al. (2004) found that both low and moderate genetic risk scores combined with increased dark fish or total EPA and DHA consumption resulted in a decreased CRC risk, while a high genetic risk score combined with an increased dark fish or total EPA and DHA consumption resulted in an increased CRC risk. When the genetic risk score was limited to six single-nucleotide polymorphisms (SNPs) associated with the transforming growth factor-beta (TGF-β) pathway, no interaction was found [27].
Song et al. (2015) conducted a prospective cohort study from which 1125 CRC cases were categorized as having microsatellite instability-high (MSI) tumors (a distinct phenotype of CRC) or microsatellite-stable (MSS) tumors. The authors found those with CpG island methylator phenotype (CIMP)-low/negative status and MSI tumors with increasing marine n-3 LC-PUFA intake (quartile 1 versus quartile 4) were associated with significantly decreased CRC risk.[28]

A post-hoc analysis of an RCT investigated the expression of chemokine C-C motif ligand 2 (CCL2), a pro-inflammatory chemokine, in 55 CRC patients with liver metastases randomized to 2g EPA daily or placebo for an average of 30 days prior to surgery [32]. They found plasma CCL2 levels post-intervention increased in the placebo group and decreased in the EPA group. In the EPA group, 614 genes were identified as differentially expressed in tumor cells from patients with decreased CCL2 plasma levels compared to patients with no change or an increase in CCL2 plasma levels. Furthermore, EPA-treated patients whose plasma CCL2 levels decreased had a significantly better disease-free survival compared with individuals in whom the plasma CCL2 level increased after supplementation. A decrease in the synthesis of CCL2 and CCL2 receptor expression was also shown by Volpato with EPA treatment in vitro, suggesting a potential mechanism of action. Additionally, although EPA is known to inhibit PGE2 synthesis and EP4 receptor activation in CRC cells, Volpato’s in vitro data demonstrated EPA’s effects on CCL2 were PGE2-EP4 receptor-independent.

3.3.1. Additional CRC Studies: Fish Intake Only

An additional four case-cohort studies/case-controlled studies [33–36] involving in total 3506 CRC cases and 7618 healthy controls were identified (see Table 2). Three of the four studies did not find any significant interactions between fish intake, genotypes and CRC risk [34–36]. The final study by Anderson et al. (2013) found that IL10 rs3024505 homozygous wild-type carriers consuming 25g of fish per day had a 10 % decreased risk of CRC while variant carriers had no risk reduction with similar intake [33].

3.3.2. Additional CRC Studies—FAP Patients

Two studies involving participants with FAP were also analyzed (see Table 2). Almendingen et al. (2007) conducted a case-controlled study and found serum phospholipid DHA levels to be lower in healthy controls versus FAP patients [37]. An RCT by West et al. (2010) involved 58 FAP patients given either 2g EPA or placebo per day for six months. The EPA-FFA group experienced a decrease in the number of polyps, diameter of polyps and global polyp burden at six months versus the placebo group [38].

3.4. Prostate Cancer Studies

Seven studies within eight reports involving PCA were identified (see Table 2). Four of the studies were case-controlled or nested case-controlled studies involving approximately 25460 PCA cases and 25800 healthy controls. These studies examined the interaction of various genotypes, fatty acid intake or levels and PCA risk and results were mostly positive [15,16,41,44]. Cheng et al. (2013) found that carriers of the myeloperoxidase (MPO) GA/AA genotype showed an increased risk of aggressive PCA with low EPA and DHA intake (quartile 1) versus carriers of the MPO GG genotype [41]. Fradet et al. (2009) found that cyclooxygenase-2 (COX-2) SNP rs4648310 AA carriers with an increasing intake of n-3 LC-PUFA was associated with a decreased risk of PCA. Furthermore, carriers of COX-2 rs4648310 (+8897 AG or GG) with low n-3 LC-PUFA intake were associated with an increased risk of PCA, and this was reversed by increasing n-3 LC-PUFA intake [15]. Hedelin et al. (2006) found that carriers of the COX-2 SNP (rs5275: 16365 T/C) who increased intake of salmon-type fish (once per week or more) versus those who never ate salmon-type fish had a decreased risk of PCA [16]. Khankari et al., (2016) with the use of a weighted PUFA-specific polygenic risk score (WPRS), found no overall association between the genetically predicted n-3 LC-PUFA evaluated and PCA risk. However, when stratified by age, modest increases in prostate cancer risk were observed for EPA among men >62 years of age [44].
Cui et al. (2016) conducted a retrospective cohort investigating the association between fatty acid desaturase (FADS) rs174537 and Cg27386326 methylation status with n-3 LC-PUFA composition and markers of n-3 LC-PUFA biosynthesis in specimens from 60 PCA patients undergoing radical prostatectomy. When comparing FADS rs174537 GG versus TT genotypes, they found that lower DHA levels in the PCA tissue was associated with the TT genotype [42].

An RCT, involving 84 PCA patients, investigated how daily supplementation of 1098 mg EPA and 549 mg DHA or 30 mg lycopene or placebo for three months modulated several gene expression pathways. A canonical pathway analysis revealed statistically significant differences in the modulation of eight gene expression pathways in the fish oil group versus the placebo group at 3 months [39,40].

Galet et al. (2014) conducted a post-hoc analysis of an RCT that randomized 55 PCA patients to either a low-fat diet plus 1000 mg EPA and 1835 mg DHA or a Western diet for 4–6 weeks prior to a radical prostatectomy. The low-fat diet supplemented with n-3 LC-PUFA resulted in a decreased prostate cancer tissue cell-cycle progression (CCP) score at post-intervention versus the Western diet group [43].

Addition Prostate Cancer Study: Fish Intake Only

Catsburg et al. (2012) conducted a case-control study in which 497 localized and 936 advanced PCA cases and 760 controls were genotyped. Carriers of the C allele of prostaglandin-endoperoxide synthase 2 (PTGS2) 765 G/C with high white fish intake had an increased risk of advanced PCA risk, while an inverse association between dark fish intake and advanced PCA risk was found among carriers of the GG allele, but not among C allele carriers [45].

3.5. Studies Involving Other Cancers

Four studies involving other cancer types were also included in this review (see Table 2). Fahrmann et al. (2013) investigated Nuclear factor Kappa B (NF-KB) activity levels in a non-randomized, uncontrolled study. Fifteen early stage chronic lymphocytic leukemia patients were supplemented with escalating n-3 LC-PUFA doses from 2.4 g to 7.2 g/day over 12 months with the highest n-3 LC-PUFA intake level associated with a decrease in NF-KB activity in subjects with higher NF-KB activity levels at baseline. There was also a significant decrease in mRNA abundance of 31 genes with higher NF-KB activity at baseline in response to n-3 LC-PUFA intake [46].

In an RCT by Cury-Boaventura et al. (2012) involving 25 surgical gastric or colon cancer, a preoperative fish oil infusion (0.2 g/kg for 3 days) altered the expression of seven genes related to cell death demonstrating a protective effect on postoperative lymphocyte apoptosis while the medium/long-chain triglycerides infusion altered 12 genes with both pro-and antiapoptotic effects associated with postoperative lymphocyte and neutrophil apoptosis [47]. In a case-control study by Huang et al. (2014), decreased gastric cancer risk was associated with increased seafood intake (≥1 time/week) in carriers of toll-like receptor 4 (TLR4) gene CC/CT rs10116253 and TT/TC rs1927911 [49].

Morales et al. (2007) conducted a case-control study involving 121 pancreatic cancer patients and found that patients with K-ras-mutated tumors had a significantly lower intake of n-3 LC-PUFA compared to those with non-K-ras-mutated tumors [48].

4. Discussion

The current scoping review suggests that human research regarding the interaction between genetic variants, dietary n-3 LC-PUFA (foods, dietary supplements, or enteral/parenteral nutrition) or tissue status, and cancer risk and/or treatment is at an inaugural stage. Several databases devoted to the genomics of cancer demonstrates how much this research is in its infancy. The Catalogue of Somatic Mutations in Cancer, for example, houses data on over a million samples, including almost 3 million coding mutations and over 100 million abnormal expression variants [52]. In contrast, the studies analyzed in this review identified only a few hundred genotypes or gene expression pathways. Nonetheless, studies identified in the current review describe a broad range of complex
interactions between functional genetic variants of cancer and n-3 LC-PUFA intake. Evidence in this review identified interactions between genetic variants of three main cancers: colorectal, prostate and breast and n-3 LC-PUFA intake. N-3 LC-PUFA exert anti-carcinogenic activity through a variety of proposed mechanisms, including decreased inflammation via the modulation of COX activity [53]. Increased risk or enhanced progression of various cancers has been attributed to COX-2 genetic variants [54,55]. The alteration of membrane dynamics and cell surface receptor function, and increased cellular oxidative stress (hypothesized to induced cancer cell apoptosis) are other anti-carcinogenic mechanisms linked to n-3 LC-PUFA [9,14,53]. The ability of n-3 LC-PUFA to regulate oncogene transcription factors has also been described, including, for example, decreased nuclear factor-kappa B (NF-kB) activity making n-3 LC-PUFA potentially useful adjunctive cancer therapy agents by sensitizing tumor cells to chemotherapy and promoting apoptosis [56].

4.1. Breast Cancer Findings

Two studies in the current review directly considered the interaction between genetic variants, breast cancer, and n-3 LC-PUFA intake. Consistent with the hypothesis that n-3 LC-PUFA may protect against cancer by promoting oxidative stress, the companion studies of Gago-Domínguez et al. (2004) [11] and Ceschi et al. (2005) [19] considered the role of GST variants in breast cancer. As glutathione-S-transferases reduce peroxidation products of oxidative stress, Gago-Domínguez et al. found that women possessing low activity GST genotypes had a lower risk of breast cancer if their diets were higher in n-3 LC-PUFA. In the same population, Ceschi and co-workers surprisingly found that the G870A variant of cyclin D1 (CCND1), which activates apoptosis in the presence of oxidative stress, reduced breast cancer risk when restricted to women with low n-3 LC-PUFA intake and high n-6 LC-PUFA intake (n-6 LC-PUFA also increases oxidative stress). High n-3 LC-PUFA intake was associated with lower risk but was not statistically significant, and levels of individual fatty acids were not measured; thus, these results should be considered preliminary.

Another identified study considered the interaction between the BRCA gene mutation or tumor hormone status and n-3 LC-PUFA or fish intake [20] and showed that those with BRCA1/2 had higher RBC DHA levels. The BRCA gene mutation, like the APC mutation in CRC, appears to strongly predict genetic risk. While only 5%–10% of breast cancers are inherited, carriers of the BRCA gene mutations account for 45%–65% of heritable breast cancer [57]. Increases in BRCA mRNA expression and protein levels in human and cell studies have been reported in response to n-3 LC-PUFA supplementation, suggesting that n-3 LC-PUFA could be an important factor in reducing breast cancer risk [50,51].

As BRCA status is commonly related to tumor ER status [57], we examined four studies that considered the role of dietary [22–25] or tissue [22] n-3 LC-PUFA and ER status, and two that considered the role of fish intake and tumor hormone status [21,24]. Overall, the association between n-3 LC-PUFA intake (and/or fish intake) and breast cancer risk is consistent with those reported by Zheng et al.’s meta-analysis [58] and found that higher dietary n-3 LC-PUFA was associated with a lower risk of breast cancer, especially in ER+/PR patients, although no association was observed for fish intake alone.

Ongoing trials currently registered in Clinicaltrials.gov appear to largely focus on the use of n-3 LC-PUFA as adjunctive treatment for breast cancer (e.g., NCT02831582; NCT02996240; NCT02278965; NCT01821833; NCT01478477) and prevention related to tumor hormone status (e.g., NCT02295059). Some of these trials may provide additional insights regarding genetic variants and dietary n-3 LC-PUFA.

4.2. Colorectal Cancer Findings

While a growing body of mechanistic evidence suggests that EPA and DHA play a protective role in CRC risk [56], evidence from human observational and clinical trials in the current review is complex and mixed. Of six studies examining an interaction between dietary DHA/EPA and gene expression or specific genetic variants in CRC risk, three found evidence suggestive of reduced risk for CRC [26,28,32], while three reported mixed results [27,30,31].
Studies reporting protective effects of dietary DHA/EPA [26,28,32] examined pathways associated with cellular inflammation. Consistent with dietary n-3 LC-PUFA as adjunctive therapy, Volpato et al. (2016) found decreased plasma CCL2, a pro-inflammatory chemokine with known roles in metastasis, and longer disease-free survival in response to supplemental EPA, in CRC subjects undergoing surgery for liver metastasis [32]. Song et al. (2015) and Habermann et al. (2013) considered pathways of inflammation activated by COX activity, known to be modulated by n-3 LC-PUFA. Song found that EPA/DHA intake was associated with a lower risk of micro-satellite instable (MSI) tumors through a proposed reduction in prostaglandin (PG) E2 pathways responsible for the loss of DNA mismatch repair activity [26,28]. Habermann et al. specifically investigated the role of dietary n-3 LC-PUFA in subjects with genetic variants known to increase PG-derived inflammatory markers (i.e., PTGS1 and PTGS2, genes of PG synthesis enzymes), and found inverse associations between CRC risk and increased intake of EPA or DHA. Consistent with an anti-inflammatory mechanism, Andersen et al. (2013) found homozygous wild-type carriers of the anti-inflammatory cytokine IL10 rs3024505 to have a significantly decreased CRC risk per increase in daily fish consumption [33].

Looking at the tumor suppressor APC gene, Theodoratou and co-workers found that low n-3 LC-PUFA intake was associated with an increased CRC risk for the wild-type and heterozygous APC 1822, but with a decreased CRC risk in those homozygous for the variant allele. This study among others, points to the complexity of genotypic nutrient interactions, and highlights the need for more intervention trials to include genotyping in evaluating therapeutic responses. APC gene defects are responsible for FAP which increases CRC risk [31]. Studies of EPA/DHA intake and status in individuals with FAP are limited. Findings from West et al. (2010) suggest that EPA supplements should be considered for chemoprevention in patients with FAP [38]. In contrast, Almendingen et al. (2006) suggest that FAP patients may have disordered fatty acid metabolism compared to healthy subjects and, as such, their optimal intakes may be different [37].

Mixed results of genotype interactions between dietary n-3 LC-PUFA versus fish consumption, may help explain the inconsistent findings of the systematic reviews and meta-analyses of CRC risk. Chen and co-workers (2015) found a non-statistically significant decreased risk of proximal colon cancer and a statistically significant increased risk of distal colon cancer with increased n-3 LC-PUFA intake in their meta-analysis, but did not examine genetic variants [59]. In contrast, Yu et al. (2014) reported a significantly reduced risk of CRC among higher fish consumers, although genetic variants were also not included. [60]. Most recently, the World Cancer Research Fund (WCRF) concluded that, although there is mechanistic evidence that dietary n-3 LC-PUFA reduce CRC risk, likely through influencing inflammatory pathways, there is limited data for a link between fish consumption and CRC risk, making the evidence “limited” but “generally consistent” for a protective effect of fish against CRC risk[61].

4.3. Prostate Cancer Findings

Of three studies finding protective benefits of n-3 LC-PUFA in Prostate cancer, Cheng and co-workers found evidence supporting increased oxidative stress as the mechanism responsible. Specifically, they examined the interaction between MPO variants and serum levels of n-3 LC-PUFA [41]. Those with the MPO GG variation were expected to have the greater ability to upregulate oxidative stress while those with GA/AA variants were compromised, i.e., with a 2-fold increase in aggressive prostate cancer risk among men with low n-3 LC-PUFA. Due to the unsaturated nature of n-3 LC-PUFA, these fatty acids are highly peroxidizable and capable of generating reactive oxygen species (ROS), which alters cellular redox states. Many tumor cells exhibit altered ROS pathways, which enable higher intracellular ROS levels in response to dietary n-3 LC-PUFA and may induce tumor cell apoptosis [53].

The remainder of studies reporting a protective benefit of fish or n-3 LC-PUFA intake investigated genetic variants associated with inflammatory pathways, again including PTGS2 and COX-2. Catsburg and co-workers (2012) found PTGS2 765 G/C genetic variants with high white fish consumption were positively associated with risk only among carriers of the C allele [45]. While those
with the PTGS2 765 G/G variant (lower inflammatory activity) exhibited a decreased risk of advanced prostate cancer with higher dark fish (higher in n-3 LC-PUFA) consumption. The authors hypothesize that the C allele may be responsible for increased PTGS2 activity (hence greater inflammation) and that interactions with heterocyclic amines may have further increased inflammatory pathways and prostate cancer risk.

Looking at variants of COX-2, Hedelin et al. (2006) found high intake of salmon-type fish but not n-3 LC-PUFA per se, among subjects who were heterozygous or homozygous for allele (C) of the SNP (rs5275: +6365 T/C) decreased prostate cancer risk by 72% [16]. It should be noted that, for many studies using a food frequency questionnaire (FFQ), intakes of each fatty acid are estimates based on subject recall, whereas blood levels of n-3 LC-PUFA are more accurate determinants of intake and tissue status [62].

Similarly, Fradet and co-workers found men with the COX-2 variant rs4648310 (+8897 A/G) to be at increased risk for prostate cancer when intake of n-3 LC-PUFA was low, but higher n-3 LC-PUFA intake was strongly protective [15]. SNP rs4648310 and rs5275 are located 2.4 kb apart and exhibit weak linkage disequilibrium in their populations, which suggests that either of these genetic variants may have effects on COX-2 activity. Evidence collectively suggests that n-3 LC-PUFA may modify prostate inflammation through the COX-2 pathway. Despite these observations, short-term supplementation of high-dose fish oil failed to reduce COX-2 gene expression in a small RCT conducted by Chan et al. (2011) [39], although they did not report the genetic variant distribution of their population.

The results of three ongoing intervention trials (in clinicaltrials.gov) promise to provide additional insights into the role on dietary n-3 LC-PUFA and prostate cancer risk and treatment (NCT02333435), with at least two of these being likely to provide evidence regarding the interaction of n-3 LC-PUFA with genetic variants (NCT03290417; NCT02176902).

4.4. Findings in Other Cancer Types

Studies involving patients with CLL [46], gastric [47,49], and pancreatic [48] cancers were also included in the current review and found specific polymorphisms of genes involved in inflammation pathways (e.g., TLR4) and cell proliferation or apoptosis (e.g., NF-kB, TRAF3, CSF1/2, K-ras oncogene) positively associated with higher intake of n-3 LC-PUFA and decreased cancer risk. Studies in these other cancer types were very limited and suggest that more clinical research is needed to elucidate potential benefits of n-3 LC-PUFA in these specific genetic variants of cancer.

4.5. Strengths and Limitations

In this scoping review, we have endeavored to provide a comprehensive summary of key study design elements on the topic of n-3 LC-PUFA and cancer that assist the reader in judging various aspects of evidence quality and strength. Scoping reviews are not intended to provide a systematic assessment of the quality or strength of evidence in a particular area [63,64], so the current review lacks a formal evaluation of risk of bias or evidence strength. It is not uncommon that, given the intent behind a scoping review to capture the state of the science on a broad topic, the study selection process can include post hoc, or modified, inclusion and exclusion criteria as new ideas emerge during the process of gathering and reviewing information [64]. Accordingly, during our study selection process, we modified our criteria to include studies that were found during screening (i.e., FAP patients and studies of fish for CRC; hormone receptor status for breast cancer) that enhanced the understanding of the research topic and strengthened our scoping review.

Due to the nature of examining a broad research question on n-3 LC-PUFA and cancer, our review identified three main cancers, yet culminated in a heterogeneous collection of studies with various polymorphisms that precludes a simple summary, but does identify varied data and mechanisms of action as well as limitations of the existing evidence base. For example, Hou et al. (2016) suggest that the discrepancy between findings for CRC risk and fish consumption versus n-3 LC-PUFA intake may be due to the source of n-3 LC-PUFA, e.g., from fish oil, purified EPA, DHA, or a combination of the two resulting in variable ratios of EPA and DHA, along with the
administration of different doses [56]. This observation is consistent with the evidence limitations for n-3 LC-PUFA and other chronic disease. For example, the potential dose–response relationship between dietary n-3 LC-PUFA and chronic disease prevention has been debated for decades in the cardiovascular disease arena, where the evidence base is much larger [65]. Additional evidence from controlled trials where n-3 LC-PUFA dosing is more defined will help evolve the evidence base regarding n-3 LC-PUFA intake level and cancer risk. Further complicating the interpretation of the current data is the use of predominately self-reported dietary intake methods [53], i.e., food frequency questionnaires, rather than biomarker data such as n-3 LC-PUFA blood/tissue levels. Food frequency questionnaires are not designed to provide an accurate estimate of absolute intake and have been criticized as a source of reporting/measurement error [66,67]. Finally, the current evidence base regarding associations between n-3 LC-PUFA intake or tissue levels and genotype-specific cancer risk is predominately observational. Chance, bias, and confounding must all be considered when interpreting results from a largely observational evidence base [68]. Randomized, controlled trials using identified genetic variants of cancer phenotypes and targeted n-3 LC-PUFA doses are needed to further assess potential anti-neoplastic response. It is hoped that insights gained from our scoping review will help further this field of investigation.

5. Conclusions

Evidence from this scoping review suggests that dietary n-3 LC-PUFA may interact with genetic variants of inflammatory signals, apoptotic gene expression markers, and cell cycle regulation factors in a manner that may decrease the risk of breast, colorectal and prostate cancer. However, depending upon the genetic polymorphism identified, a few studies found an increased risk or no benefit. Results reported in the current review require replication in large cohorts and well-powered intervention trials with genotyping to further elucidate the role of dietary n-3 LC-PUFA and genetic variation in cancer risk. Common mechanisms for n-3 LC-PUFA’ anti-neoplastic effects include the inhibition of inflammatory pathways, e.g. COX-2 activity, PTGS, CCL2, and enhanced oxidative stress pathways and apoptosis, e.g. myeloperoxidase genes and NF-kB. This review highlights variability in individual responses to n-3 LC-PUFA supplementation, some of which appear to be dose dependent. Once a genetic variant is identified, a targeted, personalized therapeutic approach that includes DHA and/or EPA may be possible as an adjuvant to immunotherapy or chemotherapy. The expansion of research designed to evaluate n-3 LC-PUFA interactions with genetic variants of other leading cancers, such as gastric, pancreatic, lung and bronchus, is also needed.

Author Contributions: All authors contributed to the original draft preparation, review and editing of this manuscript. Conceptualization, K.Y.-M.; methodology, K.Y.-M., M.V.E. and L.T.; formal analysis, K.Y.-M., M.V.E. and L.T.; investigation, K.Y.-M., M.V.E. and L.T.; resources, K.Y.-M., M.V.E. and L.T.; data curation, M.V.E. and L.T.; writing—original draft preparation, K.Y.-M., M.V.E. and L.T.; writing—review and editing, K.Y.-M., M.V.E. and L.T.; visualization, K.Y.-M., M.V.E. and L.T.; supervision, K.Y.-M.; project administration, L.T.; funding acquisition, K.Y.-M. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by DSM Nutritional Products. DSM Nutritional Products conducts research, manufactures and sells nutritional oils rich in omega-3 and omega-6 fatty acids, vitamins and other nutritional ingredients.

Acknowledgments: The authors would like to thank Robin Parker of W.K. Kellogg Health Sciences Library, Dalhousie University for her assistance in designing the search strategy for this review.

Conflicts of Interest: K.Y.M. was an employee of DSM Nutritional Products. M.V.E. and L.T. are consultants to DSM Nutritional Products and received monetary compensation from DSM for work related to this manuscript.
References

1. Ferlay, J.; Colombet, M.; Soerjomataram, I.; Mathers, C.; Parkin, D.M.; Piñeros, M.; Znaor, A.; Bray, F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 2019, 144, 1941–1953, doi:10.1002/ijc.31937.

2. Heron, M. Deaths: Leading Causes for 2017; National Center for Health Statistics: Hyattsville, MD, USA, 2019.

3. Triff, K.; Kim, E.; Chapkin, R.S. Chemoprotective epigenetic mechanisms in a colorectal cancer model: Modulation by n-3 PUFA in combination with fermentable fiber. Curr. Pharm. Rep. 2015, 1, 11–20, doi:10.1007/s40495-014-0005-7.

4. Calder, P.C. Very long-chain n-3 fatty acids and human health: Fact, fiction and the future. Proc. Nutr. Soc. 2018, 77, 52–72, doi:10.1017/s0029665117003950.

5. Gao, M.; Sun, K.; Guo, M.; Gao, H.; Liu, K.; Yang, C.; Li, S.; Liu, N. Fish consumption and n-3 polyunsaturated fatty acids, and risk of hepatocellular carcinoma: Systematic review and meta-analysis. Cancer Causes Control 2015, 26, 367–376, doi:10.1007/s10552-014-0512-1.

6. Liu, J.; Abdelmagid, S.A.; Pinelli, C.J.; Monk, J.M.; Liddle, D.M.; Hillyer, L.M.; Hucik, B.; Silva, A.; Subedi, S.; Wood, G.A., et al. Marine fish oil is more potent than plant-based n-3 polyunsaturated fatty acids in the prevention of mammary tumors. J. Nutr. Biochem. 2018, 55, 41–52, doi:10.1016/j.jnutbio.2017.12.011.

7. Liu, J.; Ma, D.W. The role of n-3 polyunsaturated fatty acids in the prevention and treatment of breast cancer. Nutrients 2014, 6, 5184–5223, doi:10.3390/nu61115184.

8. Mauermann, J.; Pouliot, F.; Fradel, V. Dietary omega-3 fatty acids, genetic variation and risk of breast and prostate cancers. In World Review of Nutrition and Dietetics; 2011; Volume 102, pp. 156–171.

9. Serini, S.; Calviello, G. Modulation of Ras/ERK and Phosphoinositide Signaling by Long-Chain n-3 PUFA in Breast Cancer and Their Potential Complementary Role in Combination with Targeted Drugs. Nutrients 2017, 9, doi:10.3390/nu9030185.

10. Yang, B.; Wang, F.L.; Ren, X.L.; Li, D. Biospecimen long-chain N-3 PUFA and risk of colorectal cancer: A meta-analysis of data from 66,627 individuals. PLoS ONE 2014, 9, e110574, doi:10.1371/journal.pone.0110574.

11. Gago-Dominguez, M.; Castelo, J.E.; Sun, C.L.; Van Den Berg, D.; Koh, W.P.; Lee, H.P.; Yu, M.C. Marine n-3 fatty acid intake, glutathione S-transferase polymorphisms and breast cancer risk in post-menopausal Chinese women in Singapore. Carcinogenesis 2004, 25, 2143–2147, doi:10.1093/carcin/bgh230.

12. Newell, M.; Brun, M.; Field, C.J. Treatment with DHA Modifies the Response of MDA-MB-231 Breast Cancer Cells and Tumors from nu/nu Mice to Doxorubicin through Apoptosis and Cell Cycle Arrest. J. Nutr. 2019, 149, 46–56, doi:10.1011/jn/ndx224.

13. VanderSluis, L.; Mazurak, V.C.; Damaraju, S.; Field, C.J. Determination of the Relative Efficacy of Eicosapentaenoic Acid and Docosahexaenoic Acid for Anti-Cancer Effects in Human Breast Cancer Models. Int. J. Mol. Sci. 2017, 18, doi:10.3390/ijms18122607.

14. Corella, D.; Ordovas, J.M. Interactions between dietary n-3 fatty acids and genetic variants and risk of disease. Br. J. Nutr. 2012, 107, 5271–5283, doi:10.1017/s0007114512001651.

15. Fradel, V.; Cheng, I.; Casey, G.; Witte, J.S. Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2009, 15, 2559–2566, doi:10.1158/1078-0432.ccr-08-2503.

16. Hedelin, M.; Chang, E.T.; Wiklund, F.; Bellocco, R.; Klint, A.; Adolfsson, J.; Shahedi, K.; Xu, J.; Adami, H.O.; Gronberg, H., et al. Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int. J. Cancer 2007, 120, 398–405, doi:10.1002/ijc.22319.

17. Khankari, N.K.; Bradshaw, P.T.; Steck, S.E.; He, K.; Olshans, A.F.; Ahn, J.; Terry, M.B.; Crew, K.D.; Teitelbaum, S.L.; Neugut, A.I., et al. Interaction between polyunsaturated fatty acids and genetic variants in relation to breast cancer incidence. J. Cancer Epidemiol. Prev. 2016, 1, 2.

18. Stern, M.C.; Siegmund, K.D.; Corral, R.; Haile, R.W. XRCC1 and XRCC3 polymorphisms and their role as effect modifiers of unsaturated fatty acids and antioxidant intake on colorectal adenomas risk. Cancer Epidemiol. Biomark. Prev. 2005, 14, 609–615, doi:10.1158/1055-9965.Epi-04-0189.

19. Ceschi, M.; Sun, C.L.; Van Den Berg, D.; Koh, W.P.; Yu, M.C.; Probst-Hensch, N. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis 2005, 26, 1457–1464, doi:10.1093/carcin/bgi093.

20. Molino, A.; Amabile, M.I.; Mazzucco, S.; Biolo, G.; Farcomeni, A.; Ramaccini, C.; Antonaroli, S.; Monti, M.; Muscaritoli, M. Effect of oral docosahexaenoic acid (DHA) supplementation on DHA levels and omega-3
index in red blood cell membranes of breast cancer patients. *Front. Physiol.* 2017, 8, doi:10.3389/fphys.2017.00549.

21. Stripp, C.; Overvad, K.; Christensen, J.; Thomsen, B.L.; Olsen, A.; Moller, S.; Tjønneland, A. Fish intake is positively associated with breast cancer incidence rate. *J. Nutr.* 2003, 133, 3664–3669.

22. Bassett, J.K.; Hodge, A.M.; English, D.R.; Macninis, R.J.; Giles, G.G. Plasma phospholipids fatty acids, dietary fatty acids, and breast cancer risk. *Cancer Causes Control* 2016, 27, 759–773, doi:10.1007/s10552-016-0753-2.

23. Kim, E.H.; Willett, W.C.; Colditz, G.A.; Hankinson, S.E.; Stampfer, M.J.; Hunter, D.J.; Rosner, B.; Holmes, M.D. Dietary fat and risk of postmenopausal breast cancer in a 20-year follow-up. *Am. J. Epidemiol.* 2006, 164, 990–997, doi:10.1093/aje/kwj309.

24. Kiyabu, G.Y.; Inoue, M.; Saito, E.; Abe, S.K.; Sawada, N.; Ishihara, J.; Iwasaki, M.; Yamaji, T.; Shimazu, T.; Sasazuki, S., et al. Fish, n3 polyunsaturated fatty acids and n6 polyunsaturated fatty acids intake and breast cancer risk: The Japan Public Health Center-based prospective study. *Int. J. Cancer* 2015, 137, 2915–2926, doi:10.1002/ijc.29672.

25. Park, S.Y.; Kolonel, L.N.; Henderson, B.E.; Wilkens, L.R. Dietary fat and breast cancer in postmenopausal women according to ethnicity and hormone receptor status: The Multiethnic Cohort Study. *Cancer Prev. Res.* 2012, 5, 216–228, doi:10.1158/1940-6207.capr-11-0260.

26. Habermann, N.; Ulrich, C.M.; Lundgreen, A.; Makar, K.W.; Poole, E.M.; Caan, B.; Kulmacz, R.; Whitton, J.; Galbraith, R.; Potter, J.D., et al. PTGS1, PTGS2, ALOX5, ALOX12, ALOX15, and FLAP SNPs: Interaction with fatty acids in colon cancer and rectal cancer. *Genes Nutr.* 2013, 8, 115–126, doi:10.1007/s12263-012-0302-x.

27. Kantor, E.D.; Lampe, J.W.; Peters, U.; Vaughan, T.L.; White, E. Long-chain omega-3 polyunsaturated fatty acid intake and risk of colorectal cancer. *Nutr. Cancer* 2014, 66, 716–727, doi:10.1080/01635381.2013.804101.

28. Song, M.; Nishihara, R.; Wu, K.; Qian, Z.R.; Kim, S.A.; Sukawa, Y.; Mima, K.; Inamura, K.; Masuda, A.; Yang, J., et al. Marine omega-3 polyunsaturated fatty acids and risk of colorectal cancer according to microsatellite instability. *J. Natl. Cancer Inst.* 2015, 107, doi:10.1093/jnci/djv007.

29. Song, M.; Nishihara, R.; Cao, Y.; Chun, E.; Qian, Z.R.; Mima, K.; Inamura, K.; Masugi, Y.; Nowak, J.A.; Nosho, K., et al. Marine omega-3 Polyunsaturated Fatty Acid Intake and Risk of Colorectal Cancer Characterized by Tumor-Infiltrating T Cells. *JAMA Oncol.* 2016, 2, 1197–1206, doi:10.1001/jamaoncol.2016.0605.

30. Stern, M.C.; Butler, L.M.; Corral, R.; Joshi, A.D.; Yuan, J.M.; Koh, W.P.; Yu, M.C. Polyunsaturated fatty acids, DNA repair single nucleotide polymorphisms and colorectal cancer in the Singapore Chinese Health Study. *J. Nutr. Nutr.* 2009, 2, 273–279, doi:10.1159/000308467.

31. Theodoratou, E.; Campbell, H.; Tenesa, A.; McNeill, G.; Cetnarskyj, R.; Barnetson, R.A.; Porteous, M.E.; Dunlop, M.G.; Farrant, S.M. Modification of the associations between lifestyle, dietary factors and colorectal cancer risk by APC variants. *Carcinogenesis* 2008, 29, 1774–1780, doi:10.1093/carcin/bgn082.

32. Volpato, M.; Perry, S.L.; Marston, G.; Ingram, N.; Cockbain, A.J.; Burghel, H.; Mann, J.; Lowes, D.; Wilson, E.; Droop, A., et al. Changes in plasma chemokine C-C motif ligand 2 levels during treatment with eicosapentaenoic acid predict outcome in patients undergoing surgery for colorectal cancer liver metastasis. *Oncotarget* 2016, 7, 28139–28150, doi:10.18632/oncotarget.8579.

33. Andersen, V.; Holst, R.; Kopp, T.I.; Tjønneland, A.; Vogel, U. Interactions between Diet, Lifestyle and IL10, IL1B, and PTGS2/COX2 Gene Polymorphisms in Relation to Risk of Colorectal Cancer in a Prospective Danish Case-Cohort Study. *PloS ONE* 2013, 8, e78366-e78366, doi:10.1371/journal.pone.0078366.

34. Luchtenborg, M.; Weijenberg, M.P.; de Goeij, A.F.; Wark, P.A.; Brink, M.; Roemen, G.M.; Lentsj, M.H.; de Bruine, A.P.; Goldbohm, R.A.; van’t Veer, P., et al. Meat and fish consumption, APC gene mutations and hMLH1 expression in colon and rectal cancer: A prospective cohort study (The Netherlands). *Cancer Causes Control* 2005, 16, 1041–1054, doi:10.1007/s10552-005-0239-0.

35. Slattery, M.L.; Curtin, K.; Wolff, R.K.; Herrick, J.S.; Caan, B.J.; Samowitz, W. Diet, physical activity, and body size associations with rectal tumor mutations and epigenetic changes. *Cancer Causes Control* 2010, 21, 1237–1245, doi:10.1007/s10552-010-9551-4.

36. Tiemersma, E.W.; Kampman, E.; Bueno de Mesquita, H.B.; Bunschoten, A.; van Schoor, H.; Kok, F.J.; Kromhout, D. Meat consumption, cigarette smoking, and genetic susceptibility in the etiology of colorectal cancer: Results from a Dutch prospective study. *Cancer Causes Control* 2002, 13, 383–393.
Nutrients 2020, 12, 1647

37. Almendingen, K.; Hostmark, A.T.; Fausa, O.; Mosdol, A.; Aabakken, L.; Vatn, M.H. Familial adenomatous polyposis patients have high levels of arachidonic acid and docosahexaenoic acid and low levels of linoleic acid and alpha-linolenic acid in serum phospholipids. *Int. J. Cancer* 2007, 120, 632–637, doi:10.1002/ijc.22337.

38. West, N.J.; Clark, S.K.; Phillips, R.K.; Hutchinson, J.M.; Leicester, R.J.; Belluzzi, A.; Hull, M.A. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. *Gut* 2010, 59, 918–925, doi:10.1136/gut.2009.09642.

39. Chan, J.M.; Weinberg, V.; Magbanua, M.J.; Sosa, E.; Simko, J.; Shinohara, K.; Federman, S.; Mattie, M.; Hughes-Fulford, M.; Haqq, C., et al. Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer. *Cancer Causes Control* 2011, 22, 141–150, doi:10.1007/s10552-010-9684-5.

40. Magbanua, M.J.M.; Roy, R.; Sosa, E.V.; Weinberg, V.; Federman, S.; Mattie, M.D.; Hughes-Fulford, M.; Simko, J.; Shinohara, K.; Haqq, C.M., et al. Gene expression and biological pathways in tissue of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation. *PLoS ONE* 2011, 6, doi:10.1371/journal.pone.0024004.

41. Cheng, T.Y.; King, I.B.; Barnett, M.J.; Ambrosone, C.B.; Thornquist, M.D.; Goodman, G.E.; Neuhausser, M.L. Serum phospholipid fatty acids, genetic variation in myeloperoxidase, and prostate cancer risk in heavy smokers: A gene-nutrient interaction in the carotene and retinol efficacy trial. *Am. J. Epidemiol.* 2013, 177, 1106–1117, doi:10.1093/aje/kws356.

42. Cui, T.; Hester, A.G.; Seeds, M.C.; Rahbar, E.; Howard, T.D.; Sergeant, S.; Chilton, F.H. Impact of Genetic and Epigenetic Variations Within the FADS Cluster on the Composition and Metabolism of Polyunsaturated Fatty Acids in Prostate Cancer. *Prostate* 2016, 76, 1182–1191, doi:10.1002/pros.23205.

43. Galet, C.; Gollapudi, K.; Stepanian, S.; Byrd, J.B.; Henning, S.M.; Grogan, T.; Elashoff, D.; Heber, D.; Said, J.; Cohen, P., et al. Effect of a low-fat fish oil diet on proinflammatory eicosanoids and cell-cycle progression score in men undergoing radical prostatectomy. *Cancer Prev. Res.* 2014, 7, 97–104, doi:10.1158/1940-6207.CAPR-13-0261.

44. Khankari, N.K.; Murff, H.J.; Zeng, C.; Wen, W.; Eeles, R.A.; Easton, D.F.; Kote-Jarai, Z.; Al Olama, A.A.; Benlloch, S.; Muir, K., et al. Polyunsaturated fatty acids and prostate cancer risk: A Mendelian randomisation analysis from the PRACTICAL consortium. *Br. J. Cancer* 2016, 115, 624–631, doi:10.1038/bjc.2016.228.

45. Catsburg, C.; Joshi, A.D.; Corral, R.; Lewinger, J.P.; Koo, J.; John, E.M.; Ingles, S.A.; Stern, M.C. Polymorphisms in carcinoegen metabolism enzymes, fish intake, and risk of prostate cancer. *Carcinogenesis* 2012, 33, 1352–1359, doi:10.1093/carcin/bgs175.

46. Farhmann, J.F.; Ballester, O.F.; Ballester, G.; Witte, T.R.; Salazar, A.I.; Kordusky, B.; Cowen, K.G.; Ion, G.; Primerano, D.A.; Boskovic, G., et al. Inhibition of nuclear factor kappa B activation in early-stage chronic lymphocytic leukemia by omega-3 fatty acids. *Cancer Investig.* 2013, 31, 29–43, doi:10.3109/07357907.2012.743553.

47. Cury-Boaventura, M.F.; Torrinhas, R.S.M.D.M.; Godoy, A.B.P.D.; Curi, R.; Waitzberg, D.L. Human leukocyte death after a preoperative infusion of medium/long-chain triglyceride and fish oil parenteral emulsions: A randomized study in gastrointestinal cancer patients. *J. Parenter. Enter. Nutr.* 2012, 36, 677–684, doi:10.1177/0148607111432759.

48. Morales, E.; Porta, M.; Vioque, J.; Lopez, T.; Mendez, M.A.; Pumarega, J.; Malats, N.; Crous-Bou, M.; Ngo, J.; Rifa, J., et al. Food and nutrient intakes and K-ras mutations in exocrine pancreatic cancer. *J. Epidemiol. Community Health* 2007, 61, 641–649, doi:10.1136/jech.2007.060632.

49. Huang, L.; Yuan, K.; Liu, J.; Ren, X.; Dong, X.; Tian, W.; Jia, Y. Polymorphisms of the TLR4 gene and risk of gastric cancer. *Gene* 2014, 537, 46–50, doi:10.1016/j.gene.2013.12.030.

50. Bernard-Gallon, D.J.; Vissac-Sabatier, C.; Antoine-Vincent, D.; Rio, P.G.; Maurizis, J.C.; Fustier, P.; Bignon, Y.J. Differential effects of n-3 and n-6 polyunsaturated fatty acids on BRCA1 and BRCA2 gene expression in breast cell lines. *Br. J. Nutr.* 2002, 87, 281–289, doi:10.1079/bjn2002522.

51. Jourdan, M.L.; Mahéo, K.; Barascu, A.; Goupille, C.; De Latour, M.P.; Bougnoux, P.; Rio, P.G. Increased BRCA1 protein in mammary tumours of rats fed marine omega-3 fatty acids. *Oncol. Rep.* 2007, 17, 713–719.

52. Yang, Y.; Dong, X.; Xie, B.; Ding, N.; Chen, J.; Li, Y.; Zhang, Q.; Qu, H.; Fang, X. Databases and web tools for cancer genomics study. *Genom. Proteom. Bioinform.* 2015, 13, 46–50, doi:10.1016/j.gpb.2015.01.005.
53. Cockbain, A.J.; Volpato, M.; Race, A.D.; Munarini, A.; Fazio, C.; Belluzzi, A.; Loadman, P.M.; Toogood, G.J.; Hull, M.A. Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. Gut 2014, 63, 1760–1768, doi:10.1136/gutjnl-2013-306445.
54. Shao, N.; Feng, N.; Wang, Y.; Mi, Y.; Li, T.; Hua, L. Systematic review and meta-analysis of COX-2 expression and polymorphisms in prostate cancer. Mol. Biol. Rep. 2012, 39, 10997–11004, doi:10.1007/s11333-012-2001-5.
55. Wang, X.F.; Huang, M.Z.; Zhang, X.W.; Hua, R.X.; Guo, W.J. COX-2-765G>C polymorphism increases the risk of cancer: A meta-analysis. PLoS ONE 2013, 8, e73213, doi:10.1371/journal.pone.0073213.
56. Hou, T.Y.; Davidson, L.A.; Kim, E.; Fan, Y.Y.; Fuentes, N.R.; Triff, K.; Chapkin, R.S. Nutrient-Gene Interaction in Colon Cancer, from the Membrane to Cellular Physiology. Annu. Rev. Nutr. 2016, 36, 543–570, doi:10.1146/annurev-nutr-071715-051039.
57. Godet, I.; Gilkes, D. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integrative cancer science and therapeutics 2017, 4, doi:10.15761/ICST.1000228
58. Zheng, J.S.; Hu, X.J.; Zhao, Y.M.; Yang, J.; Li, D. Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: Meta-analysis of data from 21 independent prospective cohort studies. BMJ Clin. Res. Ed. 2013, 346, f3706, doi:10.1136/bmj.f3706.
59. Chen, G.C.; Qin, L.Q.; Lu, D.B.; Han, T.M.; Zheng, Y.; Xu, G.Z.; Wang, X.H. N-3 polyunsaturated fatty acids intake and risk of colorectal cancer: Meta-analysis of prospective studies. Cancer Causes Control 2015, 26, 133–141, doi:10.1007/s10552-014-0492-1.
60. Yu, X.F.; Zou, J.; Dong, J. Fish consumption and risk of gastrointestinal cancers: A meta-analysis of cohort studies. World J. Gastroenterol. 2014, 20, 15398–15412, doi:10.3748/wjg.v20.i41.15398.
61. World Cancer Research Fund / American Institute for Cancer Research. Diet, Nutrition, Physical Activity and Cancer: a Global Perspective. Continuous Update Project Expert Report. Available at dietandcancerreport.org (accessed 28 May 2020)
62. Kuratko, C.N.; Salem, N., Jr. Biomarkers of DHA status. ProstaglandinsLeukot. Essent. Fat. Acids 2009, 81, 111–118, doi:10.1016/j.plfa.2009.05.007.
63. Munn, Z.; Peters, M.; Stern, C.; Tufanaru, C.; McArthur, A.; Aromatari, E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med. Res. Methodol. 2018, 18, doi:10.1186/s12861-018-0611-x.
64. Sucharew, H. Methods for Research Evidence Synthesis: The Scoping Review Approach. J. Hosp. Med. 2019, 14, 416, doi:10.12788/jhm.3248.
65. Hu, Y.; Hu, F.B.; Manson, J.E. Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants. J Am. Heart Assoc. 2019, 8, e013543, doi:10.1161/jaha.119.013543.
66. Schulze, M.B.; Martinez-González, M.A.; Fung, T.T.; Lichtenstein, A.H.; Forouhi, N.G. Food based dietary patterns and chronic disease prevention. BMJ (Clin. Res. Ed.) 2018, 361, k2396, doi:10.1136/bmj.k2396.
67. Shim, J.S.; Oh, K.; Kim, H.C. Dietary assessment methods in epidemiologic studies. Epidemiol. Health 2014, 36, e2014009, doi:10.4178/eph/e2014009.
68. Maki, K.C.; Slavin, J.L.; Rains, T.M.; Kris-Etherton, P.M. Limitations of observational evidence: Implications for evidence-based dietary recommendations. Adv. Nutr. 2014, 5, 7–15, doi:10.3945/an.113.004929.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).